Early lung cancer detection by low-dose CT screening: therapeutic implications

Expert Review of Respiratory Medicine

Volumn 11, Issue 2, 2017, Pages 89-100

  Heuvelmans, Marjolein A ^a,b   Groen, Harry J M ^a   Oudkerk, Matthijs ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Computed tomography; lung cancer; screening; stage I; treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CRYOABLATION; EARLY CANCER; EARLY CANCER DIAGNOSIS; HEAVY PARTICLE IRRADIATION; HISTOPATHOLOGY; HUMAN; LUNG LOBECTOMY; MICROWAVE THERMOTHERAPY; MINIMALLY INVASIVE SURGERY; NON SMALL CELL LUNG CANCER; OPEN SURGERY; OUTCOME ASSESSMENT; PATIENT SELECTION; PERCUTANEOUS CRYOABLATION THERAPY; PHOTODYNAMIC THERAPY; POSTOPERATIVE CARE; RADIATION DOSE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEGMENTECTOMY; STEREOTACTIC BODY RADIATION THERAPY; SUBLOBAR RESECTION; THORACOTOMY; WEDGE RESECTION; DIAGNOSTIC IMAGING; LUNG TUMOR; PATHOLOGY; PROCEDURES; THORAX RADIOGRAPHY; X-RAY COMPUTED TOMOGRAPHY;

CARCINOMA, NON-SMALL-CELL LUNG; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85010886887     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2017.1276445     Document Type: Review

References (99)

1. World Health Organisation. Cancer:fact Sheet no. 297. 2015. 2015 July 8. http://www.who.int/mediacentre/factsheets/fs297/en/.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
3. Van Klaveren RJ., Lung cancer screening. Eur J Cancer. 2011;47(Suppl 3):S147–55.
4. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project:proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the tnm classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
5. Birim O, Kappetein AP, Takkenberg JJ, et al. Survival after pathological stage IA nonsmall cell lung cancer:tumor size matters. Ann Thorac Surg. 2005;79(4):1137–1141.
6. Chansky K, Sculier JP, Crowley JJ, et al. The international association for the study of lung cancer staging project:prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792–801.
7. Naidich DP, Marshall CH, Gribbin C, et al. Low-dose CT of the lungs:preliminary observations. Radiology. 1990;175(3):729–731.
8. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg, CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395–409.•• A 20% reduction in lung cancer specific mortality was shown in participants who were screened by an annual low-dose chest CT compared to participants who were screened by chest radiography for three subsequent years.
9. Van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361(23):2221–2229.
10. Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial–overall design and results of the prevalence round. J Thorac Oncol. 2009;4(5):608–614.
11. Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with spiral CT:baseline results of the randomized DANTE trial. Lung Cancer. 2008;59(3):355–363.
12. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2009;64(1):34–40.
13. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany:study design and results of the first screening round. J Cancer Res Clin Oncol. 2012;138(9):1475–1486.
14. Humphrey LL, Deffebach M, Pappas M, et al. Screening for Lung Cancer:Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2013;159(6):411-420.
15. Centers for Medicare and Medicaid Services. Press release:national coverage determination (NCD) for lung cancer screening with low dose computed tomography (LDCT). 2015 June 28. https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2015-Press-releases-items/2015-02-05.html.
16. Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening. Eur Respir J. 2015;46(1):28–39.
17. Heuvelmans MA, Vliegenthart R, Oudkerk M. Contributions of the european trials (european randomized screening group) in computed tomography lung cancer screening. J Thorac Imaging. 2015;30(2):101-107.
18. Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the national lung screening trial. N Engl J Med. 2013;369(10):920–931.
19. Yousaf-Khan U, Van Der Aalst C, De Jong PA, et al. Final screening round of the NELSON lung cancer screening trial:the effect of a 2.5-year screening interval. Thorax. 2017;72(1):48-56.
20. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–736.
21. Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT–a model based on the Italian COSMOS trial. Cancer Prev Res (Phila). 2011;4(11):1778–1789.
22. Patz EF, Jr, Greco E, Gatsonis C, et al. Lung cancer incidence and mortality in national lung screening trial participants who underwent low-dose CT prevalence screening:a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol. 2016;17(5):590–599.
23. Heuvelmans MA, Oudkerk M. Determination of the optimal screen interval in low-dose CT lung cancer screening:are we there yet?. Transl Cancer Res. 2016;5(6):S1070–S1072.
24. Veronesi G, Maisonneuve P, Rampinelli C, et al. Computed tomography screening for lung cancer:results of ten years of annual screening and validation of cosmos prediction model. Lung Cancer. 2013;82(3):426–430.
25. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763–1771.
26. Menezes RJ, Roberts HC, Paul NS, et al. Lung cancer screening using low-dose computed tomography in at-risk individuals:the Toronto experience. Lung Cancer. 2010;67(2):177–183.
27. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS):outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med. 2008;178(9):956–961.
28. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer:five-year prospective experience. Radiology. 2005;235(1):259–265.
29. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193(5):542–551.
30. Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomography for lung cancer screening:comparison of performance between annual and biennial screen. Eur Radiol. 2016;26(11):3821-3829.
31. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with msct in germany:results of the first 3 years of follow-up after randomization. J Thorac Oncol. 2015;10(6):890–896.
32. Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the dante trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191(10):1166–1175.
33. Field JK, Duffy SW, Baldwin DR, et al. UK Lung cancer rct pilot screening trial:baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016;71(2):161–170.
34. Walter JE, Heuvelmans MA, De Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT:analysis of data from the randomised, controlled NELSON trial. Lancet Oncol. 2016;17(7):907-916.• A considerable higher lung cancer risk was shown in participants with a new nodule detected during incidence lung cancer screening. This finding may be directly translated into routine clinical practice when a patient with an incidental nodule at CT had a CT in the previous 2 years not showing the nodule. These nodules should be followed more closely than prevalent nodules to be detected in stage I.
35. Mario S, Nicola S, Carmelinda M, et al. Long-term surveillance of ground-glass nodules:evidence from the MILD trial. J Thorac Oncol. 2012;7(10):1541–1546.
36. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–714.
37. Detterbeck FC, Gibson CJ. Turning gray:the natural history of lung cancer over time. J Thorac Oncol. 2008;3(7):781–792.
38. Wao H, Mhaskar R, Kumar A, et al. Survival of patients with non-small cell lung cancer without treatment:a systematic review and meta-analysis. Syst Rev. 2013;2:10-4053-2-10.
39. Rosen JE, Salazar MC, Wang Z, et al. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2016;152(1):44–54.e9.
40. Heuvelmans MA, Oudkerk M. Management of subsolid pulmonary nodules in CT lung cancer screening. J Thorac Dis. 2015;7(7):1103–1106.
41. Yankelevitz DF, Yip R, Smith JP, et al. CT screening for lung cancer:nonsolid nodules in baseline and annual repeat rounds. Radiology. 2015;277(2):555-564.
42. Scholten ET, De Jong PA, De Hoop B, et al. Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?. Eur Respir J. 2015;45(3):765–773.
43. Louie AV, Senan S, Patel P, et al. When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?:A decision analysis. Chest. 2014;146(4):1021–1028.
44. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC:comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011;101(2):250–254.
45. Veronesi G, Bellomi M, Veronesi U, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg. 2007;84(3):959-65;discussion 965-6.
46. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax. 2011;66(4):315–319.
47. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer:diagnosis and management of lung cancer, 3rd ed:American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S.
48. American College of Chest Physicians, Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II:ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):234S–242S.
49. Luchtenborg M, Riaz SP, Coupland VH, et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol. 2013;31(25):3141–3146.
50. Donington J, Ferguson M, Mazzone P, et al. American college of chest physicians and society of thoracic surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012;142(6):1620–1635.
51. Van Der Drift MA, Karim-Kos HE, Siesling S, et al. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol. 2012;7(2):291–298.
52. Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery:diagnosis and management of lung cancer, 3rd ed:American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e166S–90S.
53. Little AG, Gay EG, Gaspar LE, et al. National survey of non-small cell lung cancer in the United States:epidemiology, pathology and patterns of care. Lung Cancer. 2007;57(3):253–260.
54. Ma L, Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer:A meta-analysis. Thorac Cancer. 2016;7(4):442–451.
55. Yang CF, Sun Z, Speicher PJ, et al. Use and outcomes of minimally invasive lobectomy for stage i non-small cell lung cancer in the national cancer data base. Ann Thorac Surg. 2016;101(3):1037–1042.
56. Burt BM, Kosinski AS, Shrager JB, et al. Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40% of normal. J Thorac Cardiovasc Surg. 2014;148(1):19-28, dicussion 28-29.e1.
57. Medbery RL, Gillespie TW, Liu Y, et al. Nodal upstaging is more common with thoracotomy than with vats during lobectomy for early-stage lung cancer:an analysis from the national cancer data base. J Thorac Oncol. 2016;11(2):222–233.
58. Swanson SJ, Herndon JE, D’Amico TA, et al. Video-assisted thoracic surgery lobectomy:report of CALGB 39802–a prospective, multi-institution feasibility study. J Clin Oncol. 2007;25(31):4993–4997.
59. Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy:a retrospective multiinstitutional database analysis. Ann Thorac Surg. 2012;93(4):1027–1032.
60. Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer:a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. 2016;49(2):602–609.
61. Nwogu CE, D’Cunha J, Pang H, et al. VATS lobectomy has better perioperative outcomes than open lobectomy:CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance). Ann Thorac Surg. 2015;99(2):399–405.
62. Bendixen M, Jorgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer:a randomised controlled trial. Lancet Oncol. 2016;17(6):836–844.• A randomized controlled trial comparing lobectomy via VATS and open lobectomy, showing less postoperative pain and a better quality of life after lobectomy via VATS. The effectiveness of the two techniques has not been described in this paper.
63. Veronesi G, Galetta D, Maisonneuve P, et al. Four-arm robotic lobectomy for the treatment of early-stage lung cancer. J Thorac Cardiovasc Surg. 2010;140(1):19–25.
64. Cerfolio RJ, Bryant AS, Skylizard L, et al. Initial consecutive experience of completely portal robotic pulmonary resection with 4 arms. J Thorac Cardiovasc Surg. 2011;142(4):740–746.
65. Mahieu J, Rinieri P, Bubenheim M, et al. Robot-assisted thoracoscopic surgery versus video-assisted thoracoscopic surgery for lung lobectomy:can a robotic approach improve short-term outcomes and operative safety?. Thorac Cardiovasc Surg. 2016;64(4):354–362.
66. Brooks P. Robotic-assisted thoracic surgery for early-stage lung cancer:A review. Aorn J. 2015;102(1):40–49.
67. Sienel W, Dango S, Kirschbaum A, et al. Sublobar resections in stage IA non-small cell lung cancer:segmentectomies result in significantly better cancer-related survival than wedge resections. Eur J Cardiothorac Surg. 2008;33(4):728–734.
68. Altorki NK, Kamel MK, Narula N, et al. Anatomical segmentectomy and wedge resections are associated with comparable outcomes for small cT1N0 non-small cell lung cancer. J Thorac Oncol. 2016;11(11):1984-1992.
69. Dai C, Shen J, Ren Y, et al. Choice of surgical procedure for patients with nsclc 1 to 2 cm among lobectomy, segmentectomy, and wedge resection:a population-based study. J Clin Oncol. 2016;34(26):3175-3182.
70. Tsutani Y, Miyata Y, Nakayama H, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma:wedge resection or segmentectomy. Chest. 2014;145(1):66–71.
71. Khullar OV, Liu Y, Gillespie T, et al. Survival after sublobar resection versus lobectomy for clinical stage ia lung cancer:an analysis from the national cancer data base. J Thorac Oncol. 2015;10(11):1625–1633.
72. Yang F, Sui X, Chen X, et al. Sublobar resection versus lobectomy in surgical treatment of elderly patients with early-stage non-small cell lung cancer (STEPS):study protocol for a randomized controlled trial. Trials. 2016;17:191.
73. Cao C, Gupta S, Chandrakumar D, et al. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non-small cell lung cancer. Ann Cardiothorac Surg. 2014;3(2):134–141.
74. Cao C, Chandrakumar D, Gupta S, et al. Could less be more?-A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. Lung Cancer. 2015;89(2):121–132.
75. Sesti J, Donington JS. Sublobar Resection:ongoing controversy for treatment for stage i non-small cell lung cancer. Thorac Surg Clin. 2016;26(3):251–259.
76. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer:a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–637.•• Pooling of randomized trials directly comparing stereotactic ablative radiotherapy and lobectomy for operable stage I NSCLC, showing that SABR could be an option for treating operable stage I NSCLC. However, this study only had a small patient sample size and short follow-up, so additional randomised studies comparing SABR with surgery in operable patients are warranted.
77. Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84(5):1060–1070.
78. Louie AV, Van Werkhoven E, Chen H, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer:results from the ROSEL multicenter randomized trial. Radiother Oncol. 2015;117(1):44–48.
79. Palma DA, Senan S. Early-stage non-small cell lung cancer in elderly patients:should stereotactic radiation therapy be the standard of care?. Int J Radiat Oncol Biol Phys. 2012;84(5):1058–1059.
80. Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer:a retrospective analysis. Lancet Oncol. 2012;13(8):802–809.
81. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. Jama. 2010;303(11):1070–1076.
82. Nanda RH, Liu Y, Gillespie TW, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients:a National Cancer Data Base analysis. Cancer. 2015;121(23):4222–4230.
83. Mancini BR, Park HS, Harder EM, et al. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. Lung Cancer. 2016;97:22–27.
84. Puri V, Crabtree TD, Bell JM, et al. Treatment outcomes in stage i lung cancer:a comparison of surgery and stereotactic body radiation therapy. J Thorac Oncol. 2015;10(12):1776–1784.
85. Eba J, Nakamura K, Mizusawa J, et al. Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma:comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A). Jpn J Clin Oncol. 2016;46(8):748-753.
86. Xiong L, Dupuy DE. Lung ablation:whats new?. J Thorac Imaging. 2016;31(4):228–237.• An update on ablative techniques for the treatment of lung cancer.
87. Sharma A, Abtin F, Shepard JA. Image-guided ablative therapies for lung cancer. Radiol Clin North Am. 2012;50(5):975–999.
88. Hiraki T, Gobara H, Iguchi T, et al. Radiofrequency ablation for early-stage nonsmall cell lung cancer. Biomed Res Int. 2014;152087:2014.
89. Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients:results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121(19):3491–3498.
90. Gobara H, Arai Y, Kobayashi T, et al. Percutaneous radiofrequency ablation for patients with malignant lung tumors:a phase II prospective multicenter study (JIVROSG-0702). Jpn J Radiol. 2016;34(8):556-563.
91. Wolf FJ, Grand DJ, Machan JT, et al. Microwave ablation of lung malignancies:effectiveness, CT findings, and safety in 50 patients. Radiology. 2008;247(3):871–879.
92. Belfiore G, Ronza F, Belfiore MP, et al. Patients’ survival in lung malignancies treated by microwave ablation:our experience on 56 patients. Eur J Radiol. 2013;82(1):177–181.
93. Yang X, Ye X, Zheng A, et al. Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer:clinical evaluation of 47 cases. J Surg Oncol. 2014;110(6):758–763.
94. Wang H, Littrup PJ, Duan Y, et al. Thoracic masses treated with percutaneous cryotherapy:initial experience with more than 200 procedures. Radiology. 2005;235(1):289–298.
95. Zemlyak A, Moore WH, Bilfinger TV. Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg. 2010;211(1):68–72.
96. Yamauchi Y, Izumi Y, Hashimoto K, et al. Percutaneous cryoablation for the treatment of medically inoperable stage I non-small cell lung cancer. Plos One. 2012;7(3):e33223.
97. Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. 2015;26(3):312–319.
98. Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):505–516.
99. Simone CB, Cengel KA. Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol. 2014;41(6):820–830.